Pradaxa Approved for Patients with Atrial Fibrillation
Links shared publicly online about this topic.
- 773total visits
Pradaxa Approved for Patients with Atrial Fibrillation
View full resource at healthcentral.com
Tags: Heart Disease, Arrhythmia, Atrial Fibrillation
Most Recently Shared on October 26, 2010 at 6:21 pm By:
healthcentral: Pradaxa Approved for Patients with Atrial Fibrillation http://bit.ly/c6DL1b Full http://bit.ly/c0NgkW
Drug recommended by NICE for stroke prevention | News | Nursing Times
nursingtimes.net — “The National Institute for Health and Clinical Excellence (NICE) has recommended the oral anticoagulant dabigatran (Pradaxa) as an option for the prevention of stroke and systemic embolism in patients with atrial fibrillation.” View full resource at nursingtimes.net
Most Recently Shared on March 18, 2012 at 12:22 am By:
News: Drug recommended by NICE for stroke prevention http://t.co/bXQbBII0
Atrial fibrillation - dabigatran etexilate
guidance.nice.org.uk — “Atrial fibrillation - dabigatran etexilate” View full resource at guidance.nice.org.uk
Most Recently Shared on March 15, 2012 at 9:40 am By:
NICE recommends dabigatran etexilate (Pradaxa) to prevent stroke and systemic embolism in patients with AF: http://t.co/sc2qhIMx
A VERY HAPPY NEW YEAR TO OUR SHU FOLLOWERS! PART 1 OF “WHAT HAPPENED TO YOUR HEART IN 2011?” Advice Information Review SmarterHeartUniversity.com Radio
smarterheartuniversity.com — “A VERY HAPPY NEW YEAR TO OUR SHU FOLLOWERS! PART 1 OF “WHAT HAPPENED TO YOUR HEART IN 2011?” Advice Information Review SmarterHeartUniversity.com Radio” View full resource at smarterheartuniversity.com
Most Recently Shared on January 2, 2012 at 8:22 pm By:
EMA updates dabigatran label due to increased fatal bleeds
cardiovascularbusiness.com — “The European Medicines Agency (EMA) has updated the safety label for Boehringer Ingelheim’s dabigatran (Pradaxa) after several cases of fatal bleeding events were reported. The number of increased bleeds may stem from the increased use of the drug as a result of approval of a new indication (preventing stroke and systemic embolism in non-valvular atrial fibrillation patients), EMA said in a statement.” View full resource at cardiovascularbusiness.com
Most Recently Shared on November 21, 2011 at 5:32 pm By:
CardioBusiness Health Magazine
EMA updates dabigatran label due to increased fatal bleeds - The European Medicines Agency (EMA) has updated the saf... http://t.co/LKyEslkQ
ACP: HospitalistWeekly - 16 November 2011
acphospitalist.org — “ACP: HospitalistWeekly - 16 November 2011” View full resource at acphospitalist.org
Most Recently Shared on November 16, 2011 at 12:00 pm By:
ACP Hospitalist Medical Journal
Tool stratifies risk of patients with acute #COPD exacerbations http://t.co/7dVxHdp6
Letter to FDA Opposing Approval of Rivaroxaban (Xarelto) for Anticoagulation Therapy in Patients With Atrial Fibrillation
citizen.org — “Letter to FDA Opposing Approval of Rivaroxaban (Xarelto) for Anticoagulation Therapy in Patients With Atrial Fibrillation” View full resource at citizen.org
Most Recently Shared on November 8, 2011 at 6:19 pm By:
Sidney Wolfe, MD Doctor, Internist, and Physician
@US_FDA ignores @Public_Citizen and expands Xarelto use to prevent strokes. See the letter we sent to the FDA. http://t.co/Qctgd29G
Xarelto Approved for Atrial Fib Patients
webmd.com — “The FDA has approved Janssen's Xarelto to prevent stroke in patients with atrial fibrillation -- with a strong black box warning.” View full resource at webmd.com
Most Recently Shared on November 4, 2011 at 10:48 pm By:
Xarelto Approved for Atrial Fib Patients: The FDA has approved Janssen's Xarelto to prevent stroke in patients w... http://t.co/vs95V0gP
FDA Okays Xarelto for Stroke Prevention - ABC News
abcnews.go.com — “The FDA has approved rivaroxaban (Xarelto) for prevention of stroke in patients with nonvalvular atrial fibrillation.” View full resource at abcnews.go.com
Most Recently Shared on November 4, 2011 at 8:11 pm By:
Tom Heston, MD Physician, Doctor, and Family Medicine Doctor
FDA Okays Xarelto for Stroke Prevention - ABC News http://t.co/u3b73w1x #health
Xarelto (Rivaroxaban) Approved By FDA For Non-Valvular Atrial Fibrillation Patients
medicalnewstoday.com — “Xarelto (rivaroxaban), an anti-clotting medication, has been approved by the FDA for patients with non-valvular atrial fibrillation to reduce stroke risk. Xarelto, a Factor Xa inhibitor, acts at a” View full resource at medicalnewstoday.com
Most Recently Shared on November 4, 2011 at 8:05 pm By:
Xarelto (Rivaroxaban) Approved By FDA For Non-Valvular Atrial Fibrillation Patients http://t.co/I5BSybmw #heart #heartdisease
Medical News: Public Citizen Calls on FDA to Nix Xarelto - in Cardiovascular, Arrhythmias from MedPage Today
medpagetoday.com — “The consumer group Public Citizen has asked the FDA not to approve rivaroxaban (Xarelto) for use in patients with atrial fibrillation because of safety and efficacy concerns.” View full resource at medpagetoday.com
Most Recently Shared on October 21, 2011 at 5:08 pm By:
Public Citizen calls on FDA to nix Xarelto: http://t.co/rwTVn8uf
Bayer, J&J Blood Thinner Gets FDA Panel Backing For New Indication
rttnews.com — “Blood thinner Xarelto, co-developed by Bayer HealthCare, a subsidiary of German chemical and pharmaceutical giant Bayer AG (BYR.L) (BAYRY.PK) and Johnson & Johnson (JNJ) won an FDA expert panel vote Thursday, backing the approval of the drug for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in the U.” View full resource at rttnews.com
Most Recently Shared on September 9, 2011 at 12:28 pm By:
Drugs and Devices OW OW Health
Bayer, J&J Stroke Drug Gets FDA Panel Backing - RTT News: USA TodayBayer, J&J Stroke Drug Gets FDA Panel B... http://t.co/ruIUBoN #drug
Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban
news-medical.net — “Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee recommended approval of rivaroxaban, a novel, once-daily, oral anticoagulant, for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation.” View full resource at news-medical.net
Most Recently Shared on September 9, 2011 at 8:24 am By:
News-Medical.Net Oncology and Health News
Oncology News: Cardiovascular and Renal Drugs Advisory Committee recommends FDA approval of J&JPRD's rivaroxaban... http://t.co/X1iH6Uy
Panel Endorses Xarelto for Stroke Prevention - QualityPoint Technologies
qualitypointtech.net — “ADELPHI, Md. (MedPage Today) -- An FDA advisory committee has voted 9-2, with one abstention, to recommend that the FDA approve the direct oral factor Xa inhibitor rivaroxaban (Xarelto) to prevent stroke in patients with nonvalvular atrial fibrillation.” View full resource at qualitypointtech.net
Most Recently Shared on September 8, 2011 at 11:45 pm By:
Panel Endorses Xarelto for Stroke Prevention: ADELPHI, Md. (MedPage Today) -- An FDA advisory committee has voted ... http://t.co/LirKpWx
FDA Recommends Against Bayer and J&J Anti-Clot Drug
ibtimes.com — “The Food and Drug Administration has recommended against an immediate approval for Bayer AG and Johnson & Johnson’s anti-clotting drug, Xarelto, as a treatment to prevent strokes in patients with atrial fibrillation.” View full resource at ibtimes.com
Most Recently Shared on September 7, 2011 at 5:25 am By:
FDA Recommends Against Bayer and J&J Drug http://t.co/ZayOjki
Bayer, J&J Suffer FDA Setback - WSJ.com
online.wsj.com — “Food and Drug Administration staff recommended against an immediate approval for Johnson & Johnson and Bayer's anticlotting drug Xarelto as a treatment to prevent strokes in patients with atrial fibrillation.” View full resource at online.wsj.com
Most Recently Shared on September 6, 2011 at 5:24 pm By:
Bayer, J&J Suffer FDA Setback http://t.co/EbYPzWd
Advertisement
